RT Journal Article
SR Electronic
A1 Nierengarten, Mary Beth
T1 FUTURE 1: Secukinumab Inhibits Radiographic Disease Progression in PsA
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 51
SP 15
OP 17
DO 10.1177/155989771451012
UL http://mdc.sagepub.com/content/14/51/15.abstract
AB This article presents the relevant radiographic data for the Efficacy at 24 Weeks and Long-Term Safety, Tolerability, and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) trial [FUTURE 1; NCT01392326]. Analysis specifically focuses on one of the secondary outcomes of the study, radiographic analysis at week 24 (primary analysis) and radiographic analysis at week 52 (secondary analysis).